Capitalization 62.76B P/E ratio 2018
-8.76x
P/E ratio 2019 -11.9x
Enterprise value 80.06B EV / Sales 2018
4.24x
EV / Sales 2019 4.98x
Free-Float
99.9%
Yield 2018
2.15%
Yield 2019 1.55%
More valuation ratios * Estimated data
Allergan Aesthetics Debuts Alle Payment Plans CI
Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21 CI
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence CI
Allergan Aesthetics Announces the Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BotoX®? Cosmetic) CI
Allergan plc Announces U.S. FDA Approval of SKINVIVE™ by JUVÉDERM® CI
Allergan Aesthetics Announces the Highly Anticipated National Launch of Juvéderm® Volux™ Xc CI
Allergan Aesthetics Announces the Launch of the Long-Awaited SkinMedica Even & Correct Collection CI
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio At the 2022 American Society for Dermatologic Surgery Meeting CI
Allergan Aesthetics Announces the Launch of SkinMedica Firm & Tone Lotion for Body CI
FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition CI
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics CI
PatientFi Expands Partnership with Allergan Aesthetics CI
Allergan plc completed the acquisition of Soliton, Inc. for approximately $570 million. CI
More news
Manager TitleAgeSince
Director of Finance/CFO 54 16-11-30
President 53 20-05-07
Director TitleAgeSince
President 53 20-05-07
Director/Board Member - 20-05-07
Director/Board Member - 20-05-07
More insiders

Other Pharmaceuticals

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-.--%+1.73% - - 63.66B
+0.99%-8.89%+87.42%+263.11% 780B
+1.13%-5.32%+66.98%+221.74% 588B
-0.29%+3.35%-9.37%-9.26% 371B
-0.06%-1.90%+13.86%+64.24% 318B
+0.75%+3.32%+20.78%+47.70% 307B
-0.95%+7.11%+1.39%-20.16% 254B
+0.12%+1.37%+13.78%+44.65% 245B
+0.30%-2.43%+6.28%+14.11% 219B
+1.41%+1.76%+43.08%+37.28% 180B
Average +0.36%-0.05%+27.13%+73.71% 332.62B
Weighted average by Cap. +0.39%-2.08%+39.15%+117.33%
See all sector performances
Ratios2018 2019
Net sales 15.79B 16.09B
Net income -5.1B -5.27B
Net Debt 21.89B 17.3B
More financial data * Estimated data
Logo Allergan plc
Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.
Employees
0
More about the company